Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. OBJECTIVE: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. DESIGN AND SETTING: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers. PATIENTS: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM). INTERVENTION: The same daily dose of hydrocortisone was administered as OD dual-release or TID. MAIN OUTCOME MEASURE: We evaluated cortisol pharmacokinetics. RESULTS: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004). CONCLUSION: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, whereas this dual-release hydrocortisone preparation was shown to slightly reduce blood pressure and HbA1c (104), such results may not always be desirable in patients with PAI.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“Dual and slowrelease formulations of cortisol may better mimic circadian hormone release (104) but do not mimic the physiological pulsatile release of cortisol.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“In men with CAH, gonadal and reproductive function are often impaired due to primary gonadal failure from TARTs and/or secondary gonadal failure due to suppressed hypothalamicpituitary-gonadal axis as a consequence of high adrenal androgen concentrations (378,437,438,625).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“The reported prevalence of TARTs in CAH ranges from 14% to 86% (437,634), with an average of 25% in adolescents, and 46% in men (378).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“TARTs are benign testicular tumors typically found in males with classic CAH (378,437).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Self-citationVgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Mastorakos, G., Vela-Bueno, A., Kales, A., & Chrousos, G. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7778 · Cited by 884 · cited 1×
“When targeting a physiological S-cortisol profile, it should also be considered that although collection of normative data has been done with care (27), there is still a concern that nighttime cortisol levels might be falsely high due to an arousal effect (stress) (28).”
(1984) · Medical Entomology and Zoology · Cited by 741
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 2×
“Studies in patients with AD have shown a more than double the standardized mortality rate (4, 5) despite contemporary optimal glucocorticoid replacement therapy.”
Self-citationRossi, R. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1440 · Cited by 419 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346 · cited 2×
“This may be higher than reported in a previous cross-sectional survey (10) studying the frequency of adrenal crises only.”
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 7×
“Oral hydrocortisone in daily divided doses is the most widely used glucocorticoid in cortisol replacement therapy (2, 3), but no formal studies of its safety and efficacy have been performed in patients with AI.”
InfluentialSelf-citationHahner, S., Loeffler, M., Fassnacht, M., Weismann, D., Koschker, A.-C., Quinkler, M., Decker, O., Arlt, W., & Allolio, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0685 · Cited by 282 · cited 1×
“The compromised QoL in AI patients (11, 12) emphasizes the need for studying QoL during a new therapeutic approach.”
Subjective health status in Norwegian patients with Addison’s disease.
Løvås, K., Loge, J. H., & Husebye, E. S. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01466.x · Cited by 256
Bensing, S., Brandt, L., Tabaroj, F., Sjöberg, O., Nilsson, B., Ekbom, A., Blomqvist, P., & Kämpe, O. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03340.x · Cited by 242 · cited 1×
“Studies in patients with AD have shown a more than double the standardized mortality rate (4, 5) despite contemporary optimal glucocorticoid replacement therapy.”
A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome
Newell‐Price, J., Trainer, P., Perry, L., Wass, J., Grossman, A., & Besser, M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02918.x · Cited by 229 · cited 1×
“When targeting a physiological S-cortisol profile, it should also be considered that although collection of normative data has been done with care (27), there is still a concern that nighttime cortisol levels might be falsely high due to an arousal effect (stress) (28).”
Eight-six Cases of Adison's Disease
Dunlop, D. (1963) · BMJ · doi:10.1136/bmj.2.5362.887 · Cited by 217
Glucocorticoid replacement therapy: are patients over treated and does it matter?
Peacey, S. R., Guo, C., Robinson, A. M., Price, A., Giles, M. A., Eastell, R., & Weetman, A. P. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.780907.x · Cited by 205 · cited 2×
“Weight reduction and increase in bone formation markers were observed when the hydrocortisone dose was decreased by 50 and 30%, respectively (14, 16).”
MethodJohannsson, G., Bergthorsdottir, R., Nilsson, A. G., Lennernas, H., Hedner, T., & Skrtic, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0170 · Cited by 173 · cited 2×
“A novel once-daily (OD) dual-release hydrocortisone tablet, based on an immediate-release coating together with an extended-release core, was developed to obtain a more physiological circadian-based S-cortisol exposuretime profile (19).”
Self-citationConstruction and validation of a fatigue impact scale for daily administration (D-FIS)
Fisk, J. D., & Doble, S. E. (2002) · Quality of Life Research · doi:10.1023/a:1015295106602 · Cited by 167 · cited 2×
“In the Fatigue Impact Scale questionnaire, the differ- encebetweenODandTIDtreatmentinpsychosocialfunc-tioning ( P (cid:1) 0.04; n (cid:1) 60), cognitive functioning ( P (cid:1) 0.054), and the total score ( P (cid:1) 0.08) were in favor of OD at 12 wk.”
InfluentialGlucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone
Løvås, K., Gjesdal, C. G., Christensen, M., Wolff, A. B., Almås, B., Svartberg, J., Fougner, K. J., Syversen, U., Bollerslev, J., Falch, J. A., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0880 · Cited by 163
Continuous subcutaneous hydrocortisone infusion in Addison’s disease
Løvås, K., & Husebye, E. S. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0052 · Cited by 155 · cited 1×
“Other studies in AI patients have shown improved well-being by better mimicking the normal serum cortisol (S-cortisol) profile by increasing the frequency of dosing of oral immediate-release tables or using a hydrocortisone infusion pump system (17, 18).”
Arlt, W., Rosenthal, C., Hahner, S., & Allolio, B. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02473.x · Cited by 144 · cited 1×
“dose-response relationship is poor (30), a crossover design”
Bottomed out: metabolic significance of the circadian trough in glucocorticoid concentrations
Dallman, M. F., Akana, S. F., Bhatnagar, S., Bell, M., & Strack, A. M. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801276 · Cited by 122 · cited 2×
“Studies in rodents have, however, shown that changing from a diurnal exposure pattern to a more continuous exposure using the same glucocorticoid dose leads to weight gain and insulin resistance (9).”
Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients
Mills, J. L., Schonberger, L. B., Wysowski, D. K., Brown, P., Durako, S. J., Cox, C., Kong, F., & Fradkin, J. E. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2003.12.036 · Cited by 118 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Corticosteroid Replacement Therapy: Twice Or Thrice Daily?
Groves, R. W., Toms, G. C., Houghton, B. J., & Monson, J. P. (1988) · Journal of the Royal Society of Medicine · doi:10.1177/014107688808100906 · Cited by 107
Self-citationGarcÍa-Borreguero, D., Wehr, T. A., Larrosa, O., Granizo, J. J., Hardwick, D., Chrousos, G. P., & Friedman, T. C. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6965 · Cited by 83 · cited 1×
“On the other hand, elevated cortisol levels between 2200 and 0400 h may have detrimental effects on sleep quality and thereby well-being in AI patients (26).”
Danilowicz, K., Bruno, O. D., Manavela, M., Gomez, R. M., & Barkan, A. (2008) · Pituitary · doi:10.1007/s11102-008-0126-2 · Cited by 72 · cited 3×
“In an attempt to improve patient outcome, studies in which both the dose and the dosing strategies were adjusted have been performed (14–16).”
Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism
Dunne, F. P., Elliot, P., Gammage, M. D., Stallard, T., Ryan, T., Sheppard, M. C., & Stewart, P. M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02928.x · Cited by 70 · cited 1×
“However, the blood pressure was unaffected when the dose of hydrocortisone was decreased from 30 to 15 mg (15).”
Self-citationAssessing the HPA axis in patients with pituitary disease: a UK survey
Reynolds, R. M., Stewart, P. M., Seckl, J. R., & Padfield, P. L. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02421.x · Cited by 48 · cited 2×
“The rationale for using TID as the comparator was based on previous data indicating improved outcome of using hydrocortisone TID as compared with twice-daily dosing (16, 17) and its common use in Europe (2, 3).”
MethodSelf-citationElbelt, U., Hahner, S., & Allolio, B. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-1003 · Cited by 37 · cited 1×
“This is supported by data showing increased insulin requirement and a tendency of increased frequency of severe hypoglycemia in patients with both AD and type 1 DM as compared with patients with type 1 DM alone (29).”
McConnell, E. M., Bell, P. M., Ennis, C., Hadden, D. R., McCance, D. R., Sheridan, B., & Atkinson, A. B. (2002) · Clinical Endocrinology · doi:10.1046/j.0300-0664.2001.01447.x · Cited by 28 · cited 1×
“Available data do not suggest that low cortisol exposure in the late evening and night constitutes a safety issue (25).”
Cited by
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769
“Dual and slowrelease formulations of cortisol may better mimic circadian hormone release (104) but do not mimic the physiological pulsatile release of cortisol.”
BackgroundInfluentialHormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Circadian clocks and insulin resistance
Stenvers, D. J., Scheer, F. A. J. L., Schrauwen, P., la Fleur, S. E., & Kalsbeek, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0122-1 · Cited by 733
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Metadata
- Authors
- Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., Wahlberg, J., Biller, B. M. K., Monson, J. P., Stewart, P. M., Lennernäs, H., & Skrtic, S.
- Affiliations
- University of Gothenburg (SE)
- Skåne University Hospital (SE)
- Umeå University (SE)
- Linköping University (SE)
- Uppsala University Hospital (SE)
- Harvard University (US)
- St Bartholomew's Hospital (GB)
- University of Birmingham (GB)
- Uppsala University (SE)
- Corresponding author
- Johannsson, G.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-02
- Volume
- 97
- Issue
- 2
- Pages
- 473-481
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2108430953
- Semantic Scholar
- 89ffc7ce5ac189e54ea0a893bc1b71924fce41b3
- Cited by
- 329
- References
- 30
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 22 · 2023: 18 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 22 · 2018: 34 · 2017: 25 · 2016: 33 · 2015: 14 · 2014: 33 · 2013: 20 · 2012: 10
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- green
- lup.lub.lu.se
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Forskningsrådet i Sydöstra Sverige
- National Institute for Health and Care Research (NF-SI-0508-10356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- adrenal insufficiency, cortisol, once-daily dosing, HbA1c, glucose metabolism, diabetes mellitus, blood pressure, body weight, sustained-release tablets
- MeSH terms
- Adrenal Insufficiency, Adult, Aged, Chemistry, Pharmaceutical, Delayed-Action Preparations, Female, Humans, Hydrocortisone, Male, Middle Aged, Time Factors, Treatment Outcome, Cross-Over Studies, Area Under Curve, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.